Catalyst Biosciences Executives
Catalyst Biosciences employs about 7 people. The company is managed by 5 executives with a total tenure of roughly 10 years, averaging almost 2.0 years of service per executive, having 1.4 employees per reported executive. Analysis of Catalyst Biosciences' management performance can provide insight into the firm performance.
| Nassim Usman CEO CEO and President and Director |
Catalyst |
Catalyst Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3824) % which means that it has lost $0.3824 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6901) %, meaning that it created substantial loss on money invested by shareholders. Catalyst Biosciences' management efficiency ratios could be used to measure how well Catalyst Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Catalyst Biosciences Workforce Comparison
Catalyst Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 125. Catalyst Biosciences holds roughly 7.0 in number of employees claiming about 6% of equities under Health Care industry.
Catalyst Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Catalyst Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Catalyst Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Catalyst Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nassim Usman over a year ago Disposition of tradable shares by Nassim Usman of Catalyst Biosciences subject to Rule 16b-3 |
Catalyst Biosciences Notable Stakeholders
A Catalyst Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Catalyst Biosciences often face trade-offs trying to please all of them. Catalyst Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Catalyst Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Nassim Usman | CEO and President and Director | Profile | |
| Ana Kapor | Sr Communications | Profile | |
| Tom DVM | Sr Devel | Profile | |
| Seline CPA | Interim Fin | Profile | |
| Grant MSc | Chief Officer | Profile |
Catalyst Biosciences Workforce Analysis
Traditionally, organizations such as Catalyst Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Catalyst Biosciences within its industry.Catalyst Biosciences Manpower Efficiency
Return on Catalyst Biosciences Manpower
| Revenue Per Employee | 113.4K | |
| Revenue Per Executive | 158.8K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 1.6M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 2.3M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |